Sarepta Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael E. Severino
- Full Time Employees
- 835
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 215 First Street Cambridge MA United States of America 02142
- IPO Date
- Jun 4, 1997
- CIK
- 0000873303
- Website
- sarepta.com
- Similar Companies
- Business
- Sarepta Therapeutics, Inc. (SRPT) is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare neuromuscular and central nervous system disorders, primarily Duchenne muscular dystrophy (DMD); its core products include FDA-approved RNA-targeted exon-skipping therapies EXONDYS 51 (eteplirsen) for exon 51 skipping, VYONDYS 53 (golodirsen) for exon 53 skipping, and AMONDYS 45 (casimersen) for exon 45 skipping, alongside the gene therapy ELEVIDYS (delandistrogene moxeparvovec-rokl) for DMD patients aged four and older with confirmed DMD gene mutations. The company advances a pipeline of over 40 programs across gene therapy, RNA technology including Morpholino oligomers and siRNA, and gene editing platforms, targeting DMD, limb-girdle muscular dystrophies (LGMDs), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), Huntington's disease, and other rare diseases; it serves patients, healthcare providers, and partners globally through manufacturing facilities and commercialization efforts. Founded in 1980 and headquartered in Cambridge, Massachusetts, with operations including a Genetic Therapies Center of Excellence in Columbus, Ohio, Sarepta targets pediatric and adult patients in the U.S. and select international markets via collaborations such as ex-U.S. rights with Roche. Recent developments include a November 2024 global licensing and collaboration agreement with Arrowhead Pharmaceuticals, providing Sarepta four clinical-stage siRNA programs for DM1, FSHD, and other neuromuscular indications plus three preclinical assets for $500 million upfront, $325 million in Arrowhead equity, and $50 million annual payments over five years, which closed in February 2025 and advanced with a $100 million milestone for the SRP-1003 DM1 program in August 2025. In June 2024, the FDA expanded ELEVIDYS approval to ambulatory and non-ambulatory DMD patients aged four and older, granting traditional approval for non-ambulatory use and accelerated approval for ambulatory; confirmatory ESSENCE study data for additional exon-skipping therapies was completed in Q3 2025, supporting planned supplemental NDA filings. Amid challenges including patient deaths linked to ELEVIDYS prompting a July 2025 restructuring with 36% workforce layoffs for $400 million in 2026 cost savings, and FDA clearance in November 2025 for a study mitigating liver injury risks, Sarepta reported Q3 2025 revenues boosted by $166.9 million in collaboration income from Roche-related milestones and Japanese approvals.
Company News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
Squarepoint Ops LLC Has $1.51 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
Comparing Alector (NASDAQ:ALEC) and Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
Canada Pension Plan Investment Board Buys Shares of 70,800 Sarepta Therapeutics, Inc. $SRPT
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated